Analysts have been eager to weigh in on the Healthcare sector with new ratings on Medtronic (MDT) and Teva Pharmaceutical Industries (TEVA).
Medtronic (MDT)
Needham analyst Michael Matson reiterated a Buy rating on Medtronic today and set a price target of $130.00. The company’s shares closed last Tuesday at $114.10, close to its 52-week high of $122.15.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 10.2% and a 64.3% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Cardiovascular Systems.
Medtronic has an analyst consensus of Strong Buy, with a price target consensus of $121.59, implying an 8.4% upside from current levels. In a report issued on November 18, Wells Fargo also maintained a Buy rating on the stock with a $127.00 price target.
See today’s analyst top recommended stocks >>
Teva Pharmaceutical Industries (TEVA)
Teva Pharmaceutical Industries received a Hold rating from Oppenheimer analyst Leland Gershell today. The company’s shares closed last Tuesday at $9.87.
According to TipRanks.com, Gershell is a 3-star analyst with an average return of 1.7% and a 41.3% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, BioMarin Pharmaceutical, and Corbus Pharmaceuticals.
Teva Pharmaceutical Industries has an analyst consensus of Hold, with a price target consensus of $10.20.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
